Dihexa is a synthetic oligopeptide designed for use in laboratory investigations into brain health and cognitive enhancement. Developed at Washington State University, Dihexa is a modified derivative of angiotensin IV that has demonstrated a capacity to enhance synapse formation and neuroregeneration in various preclinical models. Researchers are particularly interested in its ability to promote neural connectivity, making it relevant in studies of neurodegenerative conditions such as Alzheimer’s disease and traumatic brain injury.
Dihexa’s unique molecular structure gives it the ability to cross the blood-brain barrier, an important characteristic that facilitates its investigation in central nervous system (CNS) studies. It is believed to interact with the hepatocyte growth factor (HGF)/c-Met receptor system, promoting synaptic density and potentially aiding in neurorestorative processes. Unlike traditional nootropic compounds, Dihexa may offer a more direct route to promoting synaptic repair and formation.
In vitro and animal studies have shown that Dihexa may enhance cognitive performance by stimulating the growth of new neuronal connections. This has made it a compound of interest in fields ranging from age-related cognitive decline to experimental psychiatric research. However, it must be emphasized that Dihexa has not been approved for clinical use, and any implications for human outcomes remain theoretical.
At Chroma23®, we ensure that all peptide compounds, including Dihexa, are made to order to guarantee integrity and research-grade consistency. Each vial is synthesized under strict quality control conditions, accompanied by a certificate of analysis (COA) verifying its identity and purity.
Product Data
- Chemical Name: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
- Molecular Formula: C27H44N6O5
- Molecular Weight: 548.69 g/mol
- CAS Number: 1401708-83-5
